Article

A Novel Melatonergic Signature Predicts Reccurence Risk and Therapeutic Response in Breast Cancer Patients

2018-11-17

Abstract excerpt

ASMT is a key determinant of the levels of released melatonin. Though melatonin has been shown to exhibit anti-cancer activity and prevents endocrine resistance in breast cancer, the role of ASMT in breast cancer progression remains unclear. In this retrospective study, we analyzed gene expression profiles from thousands of patients and found that ASMT expression was significantly lower in breast cancer tumors re...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 653c581e-66c2-56e9-a541-bb15bab4fba0
DOI: 10.1101/472753

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

A Novel Melatonergic Signature Predicts Reccurence Risk and Therapeutic Response in Breast Cancer PatientsDOI 10.1101/472753Read

Differential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq data.Semantic proximity Read

Melatonin and Cancer HallmarksSemantic proximity Read

Melatonin pathway genes and breast cancer risk among Chinese women.Semantic proximity Read

High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagySemantic proximity Read

N6-methyladenosine modification of DYNLT1 Facilitates Tamoxifen Resistance in Luminal B Breast CancerSemantic proximity Read

AKT-Induced Tamoxifen Resistance Is Overturned by RRM2 InhibitionSemantic proximity Read

Preventing metastatic recurrence in low-risk ER/PR+ breast cancer patients – a retrospective clinical study exploring the evolving challenge of persistence with adjuvant endocrine therapySemantic proximity Read

BQ323636.1, a Novel Splice Variant to NCOR 2, as a Predictor for Tamoxifen-Resistant Breast CancerSemantic proximity Read